All In Biotech

Drug Trial Radar · NCT00300469

Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Atorvastatin Calcium Combination Therapy to Fenofibric Acid and Atorvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia

Last checked: Nov 20, 2026Latest source record: Jun 3, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 613 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

613

Actual

Start

Mar 2006

Primary completion

Feb 2007

Sponsor

Lead sponsor
AbbottIndustry
Sponsor type
Industry
First posted
Mar 9, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + atorvastatin combination therapy with ABT-335 and atorvastatin monotherapy in subjects with multiple abnormal lipid levels in the blood.

Conditions

  • Mixed Dyslipidemia
  • Coronary Heart Disease
  • Dyslipidemia

Interventions

  • ABT-335Drug

    135 mg, daily, 12 weeks

  • AtorvastatinDrug

    Daily, 12 weeks, see Arm Description for dosage information

  • PlaceboDrug

    daily, 12 weeks, see Arm Description for placebo information

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Percent Change in Triglycerides From Baseline to Final VisitTime frame: Baseline to 12 Weeks (Final Visit)
  2. Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Final VisitTime frame: Baseline to 12 Weeks (Final Visit)
  3. Mean Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Final VisitTime frame: Baseline to 12 Weeks (Final Visit)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Global Medical Information

    North Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.